NeoGenomics, Inc. (NEO) Stake Decreased by Wrapmanager Inc.

Wrapmanager Inc. trimmed its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 2.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,020 shares of the medical research company’s stock after selling 456 shares during the quarter. Wrapmanager Inc.’s holdings in NeoGenomics were worth $348,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in NeoGenomics by 26.0% during the third quarter. Bank of New York Mellon Corp now owns 882,244 shares of the medical research company’s stock worth $13,543,000 after buying an additional 182,172 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in NeoGenomics by 28.3% during the third quarter. Dimensional Fund Advisors LP now owns 965,790 shares of the medical research company’s stock worth $14,825,000 after purchasing an additional 212,937 shares during the period. Renaissance Technologies LLC boosted its position in NeoGenomics by 335.5% during the third quarter. Renaissance Technologies LLC now owns 174,652 shares of the medical research company’s stock worth $2,681,000 after purchasing an additional 134,552 shares during the period. LPL Financial LLC bought a new position in NeoGenomics during the third quarter worth $305,000. Finally, Man Group plc boosted its position in NeoGenomics by 88.1% during the third quarter. Man Group plc now owns 21,074 shares of the medical research company’s stock worth $323,000 after purchasing an additional 9,873 shares during the period. Hedge funds and other institutional investors own 76.36% of the company’s stock.

NEO stock opened at $22.92 on Wednesday. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 176.31 and a beta of 0.91. NeoGenomics, Inc. has a one year low of $11.00 and a one year high of $23.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.46.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, April 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.03. The company had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $89.71 million. NeoGenomics had a negative net margin of 0.14% and a positive return on equity of 3.07%. NeoGenomics’s quarterly revenue was up 50.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.04 earnings per share. As a group, sell-side analysts anticipate that NeoGenomics, Inc. will post 0.19 earnings per share for the current fiscal year.

NEO has been the subject of a number of research analyst reports. BidaskClub raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 29th. Zacks Investment Research cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Saturday, March 2nd. CIBC raised shares of NeoGenomics from a “neutral” rating to an “outperform” rating and reduced their price objective for the stock from $18.00 to $15.00 in a research report on Tuesday, March 12th. Finally, Needham & Company LLC lifted their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, March 29th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $20.00.

In related news, insider William Bonello sold 7,200 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $23.53, for a total value of $169,416.00. Following the completion of the transaction, the insider now owns 13,935 shares of the company’s stock, valued at $327,890.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Raymond R. Hipp sold 150,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $22.41, for a total value of $3,361,500.00. Following the transaction, the director now directly owns 256,059 shares of the company’s stock, valued at approximately $5,738,282.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 602,400 shares of company stock valued at $12,693,858. 12.20% of the stock is owned by insiders.

WARNING: This report was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/15/neogenomics-inc-neo-stake-decreased-by-wrapmanager-inc.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: What is Compound Interest?

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.